Skip to main content
Signal8

NUTRA PHARMA CORP (NPHC)

Nutra Pharma Corp. (NPHC) operates as a biopharmaceutical firm specializing in obtaining, licensing, and bringing to market a variety of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical medications. The company primarily targets the U.S. market, focusing its efforts on managing conditions such as pain, neurological ailments, cancer, autoimmune diseases, and infectious diseases. Its current commercial offerings include: Nyloxin and Nyloxin Extra Strength: These products are distributed as an oral spray for alleviating lower back pain, migraines, neck and shoulder discomfort, cramps, and neuropathic pain, and as a topical gel to relieve joint pain, arthritis, and repetitive stress injuries. Pet Pain-Away: An over-the-counter (OTC) homeopathic, non-narcotic, and non-addictive solution for chronic pain in household pets. Luxury Feet: An OTC pain reliever and anti-inflammatory designed to ease foot pain or discomfort specifically caused by high heels and stilettos. Nyloxin Military Strength: A specialized formulation for pain relief aimed at the United States Military and Veteran's Administration. Equine Pain-Away: An OTC topical pain management product for horses. Beyond its existing portfolio, Nutra Pharma Corp. is also advancing several pipeline candidates: RPI-78M: In development to treat neurological conditions such as multiple sclerosis, adrenomyeloneuropathy, and amyotrophic lateral sclerosis, alongside autoimmune diseases like rheumatoid arthritis and myasthenia gravis. RPI-MN: Under investigation for viral diseases, including human immunodeficiency virus (HIV/AIDS) and herpes, as well as for general antiviral applications. RPI-78: Being developed for applications in pain and arthritis. RPI-70: Also in development for pain relief. Founded in 2000, the company is headquartered in Plantation, Florida.

Sector: Medicinal Chemicals & Botanical Products

Industry: Drug Manufacturers - Specialty & Generic

Nutra Pharma Corp. logo

Nutra Pharma Corp.

OTC:NPHCHealthcare
$0.0001
Mkt Cap$716K
Float7.09B
O/S7.16B
Inst Own0.0%
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap$715,973
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership0.00%

based on 7.16B shares outstanding

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ExchangeOTC
CountryUSUS
IPO DateDec 6, 2001
Shares Outstanding7.16B
Float7.09B
Company Overview

Nutra Pharma Corp. (NPHC) operates as a biopharmaceutical firm specializing in obtaining, licensing, and bringing to market a variety of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical medications.

The company primarily targets the U.S. market, focusing its efforts on managing conditions such as pain, neurological ailments, cancer, autoimmune diseases, and infectious diseases.

Its current commercial offerings include: Nyloxin and Nyloxin Extra Strength: These products are distributed as an oral spray for alleviating lower back pain, migraines, neck and shoulder discomfort, cramps, and neuropathic pain, and as a topical gel to relieve joint pain, arthritis, and repetitive stress injuries. Pet Pain-Away: An over-the-counter (OTC) homeopathic, non-narcotic, and non-addictive solution for chronic pain in household pets. Luxury Feet: An OTC pain reliever and anti-inflammatory designed to ease foot pain or discomfort specifically caused by high heels and stilettos. Nyloxin Military Strength: A specialized formulation for pain relief aimed at the United States Military and Veteran's Administration. Equine Pain-Away: An OTC topical pain management product for horses. Beyond its existing portfolio, Nutra Pharma Corp. is also advancing several pipeline candidates: RPI-78M: In development to treat neurological conditions such as multiple sclerosis, adrenomyeloneuropathy, and amyotrophic lateral sclerosis, alongside autoimmune diseases like rheumatoid arthritis and myasthenia gravis. RPI-MN: Under investigation for viral diseases, including human immunodeficiency virus (HIV/AIDS) and herpes, as well as for general antiviral applications. RPI-78: Being developed for applications in pain and arthritis. RPI-70: Also in development for pain relief. Founded in 2000, the company is headquartered in Plantation, Florida.

Leadership

Dale VanderPutten

Chief Scientific Officer

Michael D. Flax

Chairman, Chief Executive Officer, President & Chief Financial Officer

Joe Lucas

Vice President of Operations

Nina Goldstein

Secretary

Employees

4

Country

US

Sector

Healthcare

Website

nutrapharma.com

Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
InsiderTypeShares
DEITSCH RIK J profile photoDEITSCH RIK JWithholding/Transfer12.00M
Shareholders
0.0%
Institutional
(1)
0.2%
Insiderⓘ
(1)
0.0%
5%+ Owners
(0)
99.8%
Unattributed (incl. retail)ⓘ
Institutional0.0%
Insider0.2%
Unattributed (incl. retail)99.8%
Top Shareholders
NameShares%
Pure Raw Supplies, LLC profile photo
Pure Raw Supplies, LLC
10% Owner
12.0M0.2%
Motiv8 Investments LLC logo
Motiv8 Investments LLC
5000.0%
Sources: 13F, Form 4O/S: 7.2B · as of 19 Aug 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

52-Week Range
$0.0001$0.0050
$0.0001(0th percentile)
Volume
Average Daily Volume301.50K
234.50K today vs 301.50K avg(-22%)

30d Avg

301.50K

60d Avg

280.67K

90d Avg

325.37K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...